Pre-diagnostic levels of sVEGFR2, sTNFR2, sIL-2Rα and sIL-6R are associated with glioma risk: A nested case-control study of repeated samples.
a nested case-control study
cytokines
glioma aetiology
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
22
11
2021
received:
27
05
2021
accepted:
23
11
2021
pubmed:
15
1
2022
medline:
19
4
2022
entrez:
14
1
2022
Statut:
ppublish
Résumé
No strong aetiological factors have been established for glioma aside from genetic mutations and variants, ionising radiation and an inverse relationship with asthmas and allergies. Our aim was to investigate the association between pre-diagnostic immune protein levels and glioma risk. We conducted a case-control study nested in the Northern Sweden Health and Disease Study cohort. We analysed 133 glioma cases and 133 control subjects matched by age, sex and date of blood donation. ELISA or Luminex bead-based multiplex assays were used to measure plasma levels of 19 proteins. Conditional logistic regression models were used to estimate the odds ratios and 95% CIs. To further model the protein trajectories over time, the linear mixed-effects models were conducted. We found that the levels of sVEGFR2, sTNFR2, sIL-2Rα and sIL-6R were associated with glioma risk. After adjusting for the time between blood sample collection and glioma diagnosis, the odds ratios were 1.72 (95% CI = 1.01-2.93), 1.48 (95% CI = 1.01-2.16) and 1.90 (95% CI = 1.14-3.17) for sTNFR2, sIL-2Rα and sIL-6R, respectively. The trajectory of sVEGFR2 concentrations over time was different between cases and controls (p-value = 0.031), increasing for cases (0.8% per year) and constant for controls. Our findings suggest these proteins play important roles in gliomagenesis.
Identifiants
pubmed: 35029050
doi: 10.1002/cam4.4505
pmc: PMC8855896
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1016-1025Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):282-90
pubmed: 26908595
Arch Med Sci. 2012 Nov 9;8(5):848-53
pubmed: 23185194
Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):19059-64
pubmed: 24190997
PLoS One. 2020 Oct 26;15(10):e0241213
pubmed: 33104754
PLoS One. 2015 Sep 09;10(9):e0137503
pubmed: 26352148
Nat Rev Neurol. 2019 Jul;15(7):405-417
pubmed: 31227792
Theranostics. 2018 Aug 07;8(16):4462-4476
pubmed: 30214632
J Neurooncol. 2017 Feb;131(3):449-458
pubmed: 27858267
FASEB J. 2001 Jan;15(1):43-58
pubmed: 11149892
Immunotherapy. 2015;7(6):655-67
pubmed: 26098609
J Neurooncol. 2011 Sep;104(2):523-7
pubmed: 21191630
Front Immunol. 2013 May 15;4:116
pubmed: 23720663
Expert Opin Ther Targets. 2019 Apr;23(4):295-307
pubmed: 30856027
Oncol Lett. 2018 Oct;16(4):4095-4104
pubmed: 30250528
PLoS One. 2017 Jun 8;12(6):e0178705
pubmed: 28594935
Br J Cancer. 2018 Oct;119(7):893-900
pubmed: 30297770
Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218
pubmed: 30480778
Cell Commun Signal. 2017 Dec 19;15(1):54
pubmed: 29258522
Cancer Med. 2022 Feb;11(4):1016-1025
pubmed: 35029050
Int J Cancer. 2011 Oct 15;129(8):2032-7
pubmed: 21154749
J Surg Oncol. 2000 Oct;75(2):131-5
pubmed: 11064393
ESMO Open. 2020 Mar;4(Suppl 3):e000629
pubmed: 32152062
Int J Cancer. 2020 Jun 15;146(12):3312-3319
pubmed: 31523805
Lab Invest. 2017 May;97(5):498-518
pubmed: 28287634
Immunol Lett. 2007 Nov 30;114(1):1-8
pubmed: 17936914
Biomarkers. 2008 Feb;13(1):1-26
pubmed: 17906988
Cancer Res. 2009 Aug 15;69(16):6482-9
pubmed: 19654312
Curr Pathobiol Rep. 2013 Mar 1;1(1):19-28
pubmed: 23538742
Glia. 2018 Jan;66(1):161-174
pubmed: 28948650
Eur J Immunol. 2010 Apr;40(4):1099-106
pubmed: 20127680
Clin Neurol Neurosurg. 2014 Apr;119:125-32
pubmed: 24582432
Cancer Res. 2017 Mar 15;77(6):1408-1415
pubmed: 28108506
Nat Genet. 2017 May;49(5):789-794
pubmed: 28346443
Neurosurg Rev. 2011 Jul;34(3):253-63; discussion 263-4
pubmed: 21656131